1
|
Wu R, Chen H, Chang N, Xu Y, Jiao J, Zhang H. Unlocking the Drug Potential of the Bryostatin Family: Recent Advances in Product Synthesis and Biomedical Applications. Chemistry 2019; 26:1166-1195. [PMID: 31479550 DOI: 10.1002/chem.201903128] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2019] [Revised: 09/01/2019] [Indexed: 12/14/2022]
Abstract
Bryostatins are a class of naturally occurring macrocyclic lactones with a unique fast developing portfolio of clinical applications, including treatment of AIDS, Alzheimer's disease, and cancer. This comprehensive account summarizes the recent progress (2014-present) in the development of bryostatins, including their total synthesis and biomedical applications. An emphasis is placed on the discussion of bryostatin 1, the most-studied analogue to date. This review highlights the synthetic and biological challenges of bryostatins and provides an outlook on their future development.
Collapse
Affiliation(s)
- Rongzhen Wu
- Department of Chemistry, Southern University of Science and Technology of China, Shenzhen, 518055, P. R. China
| | - Hongyu Chen
- Department of Biology, Southern University of Science and Technology of China, Shenzhen, 518055, P. R. China
| | - Ninghui Chang
- Department of Chemistry, School of Science, Northwestern Polytechnical University, Xi'an, 710072, P. R. China
| | - Yuzhi Xu
- School of Materials Science and Engineering, South China University of Technology, Guangzhou, 510006, P. R. China
| | - Jiao Jiao
- Department of Chemistry, School of Science, Xi'an Key Laboratory of Sustainable Energy Materials Chemistry, Xi'an Jiaotong University, Xi'an, 710049, P. R. China
| | - Hailong Zhang
- School of Pharmacy, Xi'an Jiaotong University, Xi'an, 710061, P. R. China
| |
Collapse
|
2
|
Crane EA, Gademann K. Synthetisch gewonnene Naturstofffragmente in der Wirkstoffentwicklung. Angew Chem Int Ed Engl 2016. [DOI: 10.1002/ange.201505863] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- Erika A. Crane
- Departement Chemie; Universität Basel; St. Johanns-Ring 19 CH-4056 Basel Schweiz
| | - Karl Gademann
- Departement Chemie; Universität Basel; St. Johanns-Ring 19 CH-4056 Basel Schweiz
- Institut für Chemie; Universität Zürich; Winterthurerstrasse 190 CH-8057 Zürich Schweiz
| |
Collapse
|
3
|
Crane EA, Gademann K. Capturing Biological Activity in Natural Product Fragments by Chemical Synthesis. Angew Chem Int Ed Engl 2016; 55:3882-902. [PMID: 26833854 PMCID: PMC4797711 DOI: 10.1002/anie.201505863] [Citation(s) in RCA: 106] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2015] [Indexed: 12/22/2022]
Abstract
Natural products have had an immense influence on science and have directly led to the introduction of many drugs. Organic chemistry, and its unique ability to tailor natural products through synthesis, provides an extraordinary approach to unlock the full potential of natural products. In this Review, an approach based on natural product derived fragments is presented that can successfully address some of the current challenges in drug discovery. These fragments often display significantly reduced molecular weights, reduced structural complexity, a reduced number of synthetic steps, while retaining or even improving key biological parameters such as potency or selectivity. Examples from various stages of the drug development process up to the clinic are presented. In addition, this process can be leveraged by recent developments such as genome mining, antibody–drug conjugates, and computational approaches. All these concepts have the potential to identify the next generation of drug candidates inspired by natural products.
Collapse
Affiliation(s)
- Erika A Crane
- Department of Chemistry, University of Basel, Switzerland
| | - Karl Gademann
- Department of Chemistry, University of Basel, Switzerland. .,Department of Chemistry, University of Zürich, Winterthurerstrasse 190, CH-8057, Zürich, Switzerland.
| |
Collapse
|
4
|
Andrews IP, Ketcham JM, Blumberg PM, Kedei N, Lewin N, Peach ML, Krische MJ. Synthesis of seco-B-ring bryostatin analogue WN-1 via C-C bond-forming hydrogenation: critical contribution of the B-ring in determining bryostatin-like and phorbol 12-myristate 13-acetate-like properties. J Am Chem Soc 2014; 136:13209-16. [PMID: 25207655 PMCID: PMC4183601 DOI: 10.1021/ja507825s] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2014] [Indexed: 01/31/2023]
Abstract
The seco-B-ring bryostatin analogue, macrodiolide WN-1, was prepared in 17 steps (longest linear sequence) and 30 total steps with three bonds formed via hydrogen-mediated C-C coupling. This synthetic route features a palladium-catalyzed alkoxycarbonylation of a C2-symmetric diol to form the C9-deoxygenated bryostatin A-ring. WN-1 binds to PKCα (Ki = 16.1 nM) and inhibits the growth of multiple leukemia cell lines. Although structural features of the WN-1 A-ring and C-ring are shared by analogues that display bryostatin-like behavior, WN-1 displays PMA-like behavior in U937 cell attachment and proliferation assays, as well as in K562 and MV-4-11 proliferation assays. Molecular modeling studies suggest the pattern of internal hydrogen bonds evident in bryostatin 1 is preserved in WN-1, and that upon docking WN-1 into the crystal structure of the C1b domain of PKCδ, the binding mode of bryostatin 1 is reproduced. The collective data emphasize the critical contribution of the B-ring to the function of the upper portion of the molecule in conferring a bryostatin-like pattern of biological activity.
Collapse
Affiliation(s)
- Ian P. Andrews
- Department
of Chemistry and Biochemistry, University
of Texas at Austin, Austin, Texas 78712, United States
| | - John M. Ketcham
- Department
of Chemistry and Biochemistry, University
of Texas at Austin, Austin, Texas 78712, United States
| | - Peter M. Blumberg
- Laboratory
of Cancer Biology and Genetics, National
Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4255, United States
| | - Noemi Kedei
- Laboratory
of Cancer Biology and Genetics, National
Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4255, United States
| | - Nancy
E. Lewin
- Laboratory
of Cancer Biology and Genetics, National
Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4255, United States
| | - Megan L. Peach
- Basic Science Program,
Leidos Biomedical Research, Inc., Chemical Biology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702, United States
| | - Michael J. Krische
- Department
of Chemistry and Biochemistry, University
of Texas at Austin, Austin, Texas 78712, United States
| |
Collapse
|
5
|
Wender PA, Staveness D. Improved protein kinase C affinity through final step diversification of a simplified salicylate-derived bryostatin analog scaffold. Org Lett 2014; 16:5140-3. [PMID: 25238640 PMCID: PMC4334251 DOI: 10.1021/ol502492b] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
![]()
Bryostatin
1, in clinical
trials or preclinical development for cancer, Alzheimer’s disease,
and a first-of-its-kind strategy for HIV/AIDS eradication, is neither
readily available nor optimally suited for clinical use. In preceding
work, we disclosed a new class of simplified bryostatin analogs designed
for ease of access and tunable activity. Here we describe a final
step diversification strategy that provides, in only 25 synthetic
steps, simplified and tunable analogs with bryostatin-like PKC modulatory
activities.
Collapse
Affiliation(s)
- Paul A Wender
- Departments of Chemistry and Chemical and Systems Biology, Stanford University , Stanford, California 94305, United States
| | | |
Collapse
|
6
|
Wender PA, Donnelly AC, Loy BA, Near KE, Staveness D. Rethinking the Role of Natural Products: Function-Oriented Synthesis, Bryostatin, and Bryologs. METHODS AND PRINCIPLES IN MEDICINAL CHEMISTRY 2014. [DOI: 10.1002/9783527676545.ch14] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
|
7
|
Cragg GM, Grothaus PG, Newman DJ. New horizons for old drugs and drug leads. JOURNAL OF NATURAL PRODUCTS 2014; 77:703-23. [PMID: 24499205 DOI: 10.1021/np5000796] [Citation(s) in RCA: 168] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
There is mounting urgency to find new drugs for the treatment of serious infectious diseases and cancer that are rapidly developing resistance to previously effective drugs. One approach to addressing this need is through drug repurposing, which refers to the discovery of new useful activities for "old" clinically used drugs through screening them against relevant disease targets. A large number of potential drug that, for various reasons, have failed to advance to clinical and commercial use can be added to the candidates available for such purposes. The application of new techniques and methodology developed through the impressive progress made in multidisciplinary, natural product-related research in recent years should aid substantially in expediting the discovery and development process. This review briefly outlines some of these developments as applied to a number of selected natural product examples, which may also include advances in chemical synthesis of derivatives with extended biological activities.
Collapse
Affiliation(s)
- Gordon M Cragg
- Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory , P.O. Box B, Frederick, Maryland 21702, United States
| | | | | |
Collapse
|
8
|
Microbial natural products: molecular blueprints for antitumor drugs. J Ind Microbiol Biotechnol 2013; 40:1181-210. [PMID: 23999966 DOI: 10.1007/s10295-013-1331-1] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2013] [Accepted: 08/07/2013] [Indexed: 12/18/2022]
Abstract
Microbes from two of the three domains of life, the Prokarya, and Eukarya, continue to serve as rich sources of structurally complex chemical scaffolds that have proven to be essential for the development of anticancer therapeutics. This review describes only a handful of exemplary natural products and their derivatives as well as those that have served as elegant blueprints for the development of novel synthetic structures that are either currently in use or in clinical or preclinical trials together with some of their earlier analogs in some cases whose failure to proceed aided in the derivation of later compounds. In every case, a microbe has been either identified as the producer of secondary metabolites or speculated to be involved in the production via symbiotic associations. Finally, rapidly evolving next-generation sequencing technologies have led to the increasing availability of microbial genomes. Relevant examples of genome mining and genetic manipulation are discussed, demonstrating that we have only barely scratched the surface with regards to harnessing the potential of microbes as sources of new pharmaceutical leads/agents or biological probes.
Collapse
|
9
|
Wang T, Hao XQ, Huang JJ, Niu JL, Gong JF, Song MP. Chiral Bis(imidazolinyl)phenyl NCN Pincer Rhodium(III) Catalysts for Enantioselective Allylation of Aldehydes and Carbonyl–Ene Reaction of Trifluoropyruvates. J Org Chem 2013; 78:8712-21. [DOI: 10.1021/jo4014194] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- Tao Wang
- Henan Key Laboratory of Chemical
Biology and Organic Chemistry, The College of Chemistry and Molecular
Engineering, Zhengzhou University, Zhengzhou 450052, People’s Republic of China
| | - Xin-Qi Hao
- Henan Key Laboratory of Chemical
Biology and Organic Chemistry, The College of Chemistry and Molecular
Engineering, Zhengzhou University, Zhengzhou 450052, People’s Republic of China
| | - Juan-Juan Huang
- Henan Key Laboratory of Chemical
Biology and Organic Chemistry, The College of Chemistry and Molecular
Engineering, Zhengzhou University, Zhengzhou 450052, People’s Republic of China
| | - Jun-Long Niu
- Henan Key Laboratory of Chemical
Biology and Organic Chemistry, The College of Chemistry and Molecular
Engineering, Zhengzhou University, Zhengzhou 450052, People’s Republic of China
| | - Jun-Fang Gong
- Henan Key Laboratory of Chemical
Biology and Organic Chemistry, The College of Chemistry and Molecular
Engineering, Zhengzhou University, Zhengzhou 450052, People’s Republic of China
| | - Mao-Ping Song
- Henan Key Laboratory of Chemical
Biology and Organic Chemistry, The College of Chemistry and Molecular
Engineering, Zhengzhou University, Zhengzhou 450052, People’s Republic of China
| |
Collapse
|